Zacks: Brokerages Expect Arrowhead Pharmaceuticals, Inc. (ARWR) to Announce -$0.14 EPS
Equities research analysts expect that Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) will report earnings per share of ($0.14) for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Arrowhead Pharmaceuticals’ earnings. The highest EPS estimate is ($0.07) and the lowest is ($0.18). Arrowhead Pharmaceuticals reported earnings of ($0.31) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 54.8%. The business is scheduled to report its next quarterly earnings report on Wednesday, December 13th.
According to Zacks, analysts expect that Arrowhead Pharmaceuticals will report full year earnings of ($0.54) per share for the current year, with EPS estimates ranging from ($0.72) to ($0.39). For the next financial year, analysts forecast that the company will report earnings of ($0.64) per share, with EPS estimates ranging from ($0.88) to ($0.42). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Arrowhead Pharmaceuticals.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.06. The business had revenue of $9.34 million for the quarter, compared to analyst estimates of $5.29 million. Arrowhead Pharmaceuticals had a negative return on equity of 46.73% and a negative net margin of 201.84%.
A number of research analysts have commented on ARWR shares. Jefferies Group LLC restated a “hold” rating and issued a $2.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, April 12th. ValuEngine downgraded Arrowhead Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Finally, Piper Jaffray Companies restated a “hold” rating and issued a $2.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Friday, July 28th. One equities research analyst has rated the stock with a sell rating and five have issued a hold rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $1.80.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Teachers Advisors LLC increased its position in shares of Arrowhead Pharmaceuticals by 18.0% in the fourth quarter. Teachers Advisors LLC now owns 112,642 shares of the biotechnology company’s stock worth $175,000 after buying an additional 17,201 shares during the period. Wells Fargo & Company MN increased its position in shares of Arrowhead Pharmaceuticals by 144.8% in the first quarter. Wells Fargo & Company MN now owns 150,346 shares of the biotechnology company’s stock worth $278,000 after buying an additional 88,933 shares during the period. Bank of New York Mellon Corp increased its position in shares of Arrowhead Pharmaceuticals by 3.7% in the first quarter. Bank of New York Mellon Corp now owns 314,034 shares of the biotechnology company’s stock worth $581,000 after buying an additional 11,099 shares during the period. UBS Asset Management Americas Inc. increased its position in shares of Arrowhead Pharmaceuticals by 414.7% in the first quarter. UBS Asset Management Americas Inc. now owns 66,400 shares of the biotechnology company’s stock worth $123,000 after buying an additional 53,500 shares during the period. Finally, SG Americas Securities LLC increased its position in shares of Arrowhead Pharmaceuticals by 287.9% in the first quarter. SG Americas Securities LLC now owns 100,747 shares of the biotechnology company’s stock worth $186,000 after buying an additional 74,776 shares during the period. Hedge funds and other institutional investors own 30.13% of the company’s stock.
Arrowhead Pharmaceuticals (ARWR) opened at 1.84 on Monday. The stock has a 50 day moving average price of $1.62 and a 200 day moving average price of $1.76. Arrowhead Pharmaceuticals has a 1-year low of $1.20 and a 1-year high of $8.22. The firm’s market capitalization is $137.58 million.
WARNING: This news story was posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://www.americanbankingnews.com/2017/08/07/zacks-brokerages-expect-arrowhead-pharmaceuticals-inc-arwr-to-announce-0-14-eps.html.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arrowhead Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.